Research progress of sequential immunotherapy for neuromyelitis optica spectrum disorders in children
10.3760/cma.j.cn101070-20200407-00591
- VernacularTitle:儿童视神经脊髓炎谱系疾病序贯免疫治疗研究进展
- Author:
Zhichao LI
1
;
Lin WAN
;
Guang YANG
Author Information
1. 解放军医学院，北京 100853
- Keywords:
Neuromyelitis optica spectrum disorders;
Child;
Immunotherapy;
Rituximab
- From:
Chinese Journal of Applied Clinical Pediatrics
2021;36(18):1431-1433
- CountryChina
- Language:Chinese
-
Abstract:
Pediatric neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory demyelinating di-sease spectrum of the central nervous system, mainly involving the optic nerve and spinal cord.Due to the high disability and recurrence rate, sequential immunotherapy is usually needed to prevent the recurrence of NMOSD after acute treatment.Among the commonly used immune suppressants, Rituximab and Mycophenolate mofetil are the preferred drugs due to the best efficacy.Drug tolerance of Mycophenolate mofetil is better than that of Rituximab, and that of Cyclophosphamide remains the worst.Azathioprine is not recommended as the first-line drug of NMOSD because of frequent adverse events and the slow onset.This study aims to review the sequential immunotherapy of NMOSD in children.
